Humacyte, Inc.(HUMA)Earnings, Financials & Key Ratios
HUMA•NASDAQ
$1.08
$140M mkt cap·Price updated May 7, 2026
AboutHumacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.Show more
- Revenue$0
- EBITDA-$107M-16.1%
- Net Income-$149M-34.2%
- EPS (Diluted)-1.26-17.8%
- Interest Coverage-12.33+18.7%
HUMA Key Insights
Humacyte, Inc. (HUMA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Weak momentum: RS Rating 10 (bottom 10%)
- ✗Shares diluted 14.6% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
HUMA Price & Volume
Humacyte, Inc. (HUMA) stock price & volume — 10-year historical chart
Loading chart...
HUMA Growth Metrics
Humacyte, Inc. (HUMA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM75.82%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM82.84%
Return on Capital
10 Years-59.04%
5 Years-59.99%
3 Years-68.39%
Last Year-100.48%
HUMA Recent Earnings
Humacyte, Inc. (HUMA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 2/12 qtrs (33%)
Q2 2026Latest
Mar 27, 2026EPS
$0.13
Est $0.13
+0.0%
Revenue
$467,000
Est $1M
-65.4%
Q4 2025
Nov 12, 2025EPS
$0.14
Est $0.17
+17.6%
Revenue
$753,000
Est $1M
-44.2%
Q3 2025
Aug 11, 2025EPS
$0.24
Est $0.15
-60.0%
Revenue
$301,000
Est $917,830
-67.2%
Q2 2025
May 13, 2025EPS
$0.10
Est $0.19
+47.4%
Revenue
$517,000
Est $764,830
-32.4%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 27, 2026 | $0.13vs $0.13+0.0% | $467,000vs $1M-65.4% |
| Q4 2025 | Nov 12, 2025 | $0.14vs $0.17+17.6% | $753,000vs $1M-44.2% |
| Q3 2025 | Aug 11, 2025 | $0.24vs $0.15-60.0% | $301,000vs $917,830-67.2% |
| Q2 2025 | May 13, 2025 | $0.10vs $0.19+47.4% | $517,000vs $764,830-32.4% |
Based on last 12 quarters of dataView full earnings history →
HUMA Peer Comparison
Humacyte, Inc. (HUMA) competitors in Regenerative Medicine and Tissue Engineering — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 TELA | 44.38M | 1.10 | -0.83 | 18.56% | -50.61% | -272.13% | 1.51 | |
 NVCR | 1.92B | 16.83 | -13.80 | 8.28% | -25.66% | -50.82% | 0.85 | |
 ATRC | 1.41B | 27.80 | -115.83 | 14.88% | -0.83% | -0.95% | 0.18 | |
 ANGO | 468.54M | 11.27 | -13.58 | -3.76% | -9.02% | -15.71% | ||
 AORT | 1.72B | 35.39 | 168.52 | 13.59% | 2.55% | 2.66% | 0.65 | |
 ELMD | 222.39M | 26.86 | 31.23 | 16.97% | 13.06% | 19.79% | 0.00 | |
 LMAT | 2.46B | 107.91 | 42.82 | 13.53% | 24.35% | 16.19% | 0.47 | |
 BDX | 55.53B | 153.26 | 26.29 | 8.23% | 5.33% | 4.54% | 0.76 |
Compare HUMA vs Peers
Humacyte, Inc. (HUMA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
HUMA Income Statement
Humacyte, Inc. (HUMA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 6.19M | 1.49M | 1.26M | 1.56M | 0 | 0 | 8.8M |
| Revenue Growth % | - | -75.9% | -15.29% | 23.91% | -100% | - | - |
| Cost of Goods Sold | 75.6M | 54.08M | 61.34M | 8.26M | 76.55M | 7.19M | 7.93M |
| COGS % of Revenue | 1221.97% | 3626.96% | 4856.77% | 527.48% | - | - | - |
| Gross Profit | -69.42M▲ 0% | -52.59M▲ 24.2% | -60.08M▼ 14.2% | -6.69M▲ 88.9% | -76.55M▼ 1044.2% | -7.19M▲ 90.6% | 873K▲ 0% |
| Gross Margin % | -1121.97% | -3526.96% | -4756.77% | -427.48% | - | - | 9.92% |
| Gross Profit Growth % | - | 24.24% | -14.24% | 88.86% | -1044.25% | 90.61% | - |
| Operating Expenses | 16.27M | 12.01M | 21.13M | 77.89M | 23.5M | 107.21M | 106.26M |
| OpEx % of Revenue | 263.05% | 805.7% | 1673% | 4976.87% | - | - | - |
| Selling, General & Admin | 16.27M | 12.01M | 21.13M | 22.88M | 20.39M | 25.8M | 34.6M |
| SG&A % of Revenue | 263.05% | 805.7% | 1673% | 1462.17% | - | - | - |
| Research & Development | 75.6M | 54.08M | 61.34M | 63.26M | 76.55M | 88.6M | 75.35M |
| R&D % of Revenue | 1221.97% | 3626.96% | 4856.77% | 4042.17% | - | - | - |
| Other Operating Expenses | -75.6M | -54.08M | -61.34M | -8.26M | -73.44M | -7.19M | -2M |
| Operating Income | -85.69M▲ 0% | -64.6M▲ 24.6% | -81.21M▼ 25.7% | -84.58M▼ 4.1% | -100.05M▼ 18.3% | -114.4M▼ 14.3% | -105.39M▲ 0% |
| Operating Margin % | -1385.02% | -4332.66% | -6429.77% | -5404.35% | - | - | -1197.74% |
| Operating Income Growth % | - | 24.61% | -25.71% | -4.15% | -18.29% | -14.34% | - |
| EBITDA | -78.94M | -56.25M | -72.97M | -76.37M | -92.33M | -107.21M | -98.02M |
| EBITDA Margin % | -1275.93% | -3772.57% | -5777.28% | -4879.74% | - | - | -1114.04% |
| EBITDA Growth % | - | 28.75% | -29.72% | -4.66% | -20.9% | -16.12% | 5.46% |
| D&A (Non-Cash Add-back) | 6.75M | 8.35M | 8.24M | 8.21M | 7.72M | 7.19M | 7.37M |
| EBIT | -85.69M | -64.6M | -81.21M | -84.58M | -104.18M | -139.42M | -26.3M |
| Net Interest Income | -2.03M | -1.92M | -4.33M | -3.57M | -1.13M | -5.17M | -7.73M |
| Interest Income | 269K | 278K | 16K | 2.63M | 5.47M | 4.1M | 2.94M |
| Interest Expense | 2.3M | 2.2M | 4.35M | 6.2M | 6.6M | 9.28M | 10.66M |
| Other Income/Expense | 269K | -1.92M | 54.73M | 72.61M | -10.73M | -34.3M | 68.42M |
| Pretax Income | -85.42M▲ 0% | -66.52M▲ 22.1% | -26.48M▲ 60.2% | -11.96M▲ 54.8% | -110.78M▼ 825.8% | -148.7M▼ 34.2% | -36.97M▲ 0% |
| Pretax Margin % | -1380.67% | -4461.7% | -2096.36% | -764.54% | - | - | -420.15% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -85.42M▲ 0% | -66.52M▲ 22.1% | -26.48M▲ 60.2% | -11.96M▲ 54.8% | -110.78M▼ 825.8% | -148.7M▼ 34.2% | -36.97M▲ 0% |
| Net Margin % | -1380.67% | -4461.7% | -2096.36% | -764.54% | - | - | -420.15% |
| Net Income Growth % | - | 22.12% | 60.2% | 54.81% | -825.83% | -34.24% | 75.82% |
| Net Income (Continuing) | -85.42M | -66.52M | -26.48M | -11.96M | -110.78M | -148.7M | -36.97M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -4.25▲ 0% | -5.52▼ 29.9% | -0.66▲ 88.0% | -0.12▲ 81.8% | -1.07▼ 791.7% | -1.26▼ 17.8% | -0.23▲ 0% |
| EPS Growth % | - | -29.88% | 88.04% | 81.82% | -791.67% | -17.76% | 82.84% |
| EPS (Basic) | -4.25 | -5.52 | -0.66 | -0.12 | -1.07 | -1.26 | - |
| Diluted Shares Outstanding | 20.12M | 12.45M | 39.97M | 103.05M | 103.42M | 118.48M | 158.31M |
| Basic Shares Outstanding | 20.12M | 12.45M | 39.97M | 103.05M | 103.42M | 118.48M | 158.31M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
HUMA Balance Sheet
Humacyte, Inc. (HUMA) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 94.95M | 41.45M | 229.34M | 154.21M | 83.28M | 47.86M | 41.35M |
| Cash & Short-Term Investments | 93.71M | 39.93M | 225.5M | 151.88M | 80.45M | 44.94M | 19.49M |
| Cash Only | 93.71M | 39.93M | 217.5M | 149.77M | 80.45M | 44.94M | 19.49M |
| Short-Term Investments | 0 | 0 | 8M | 2.11M | 0 | 0 | 0 |
| Accounts Receivable | 601K | 113K | 176K | 31K | 0 | 0 | 1.08M |
| Days Sales Outstanding | 35.46 | 27.66 | 50.86 | 7.23 | - | - | 20.33 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 18.42M |
| Days Inventory Outstanding | - | - | - | - | - | - | 431.79 |
| Other Current Assets | 0 | 0 | 0 | 2.3M | 2.83M | 2.92M | 2.37M |
| Total Non-Current Assets | 73.74M | 65.24M | 57.19M | 50.09M | 44.95M | 90.01M | 50.16M |
| Property, Plant & Equipment | 73.74M | 65.24M | 57.19M | 50.09M | 44.1M | 38.55M | 49.28M |
| Fixed Asset Turnover | 0.08x | 0.02x | 0.02x | 0.03x | - | - | 0.22x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 841K | 51.46M | 155.22M |
| Total Assets | 168.69M▲ 0% | 106.69M▼ 36.8% | 286.53M▲ 168.6% | 204.3M▼ 28.7% | 128.22M▼ 37.2% | 137.87M▲ 7.5% | 91.51M▲ 0% |
| Asset Turnover | 0.04x | 0.01x | 0.00x | 0.01x | - | - | 0.07x |
| Asset Growth % | - | -36.76% | 168.57% | -28.7% | -37.24% | 7.53% | -11.69% |
| Total Current Liabilities | 10.84M | 11.23M | 11.05M | 19.58M | 18.44M | 19.95M | 25.58M |
| Accounts Payable | 3.27M | 2.27M | 2.09M | 1.59M | 6.49M | 4.49M | 9.57M |
| Days Payables Outstanding | 15.8 | 15.35 | 12.46 | 70.52 | 30.95 | 227.93 | 302.39 |
| Short-Term Debt | 1.5M | 2.45M | 0 | 8.57M | 0 | 0 | 2.67M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | -1.5M | 1.15M | 4.12M | 4.23M | 5.29M | 7.37M | 13.34M |
| Current Ratio | 8.76x | 3.69x | 20.75x | 7.88x | 4.52x | 2.40x | 2.40x |
| Quick Ratio | 8.76x | 3.69x | 20.75x | 7.88x | 4.52x | 2.40x | 2.40x |
| Cash Conversion Cycle | - | - | - | - | - | - | 149.72 |
| Total Non-Current Liabilities | 25.65M | 24.78M | 153.31M | 67.79M | 96.23M | 170.59M | 70.68M |
| Long-Term Debt | 0 | 822K | 27.36M | 20.34M | 38.6M | 0 | 27.16M |
| Capital Lease Obligations | 25.65M | 23.82M | 21.79M | 18.85M | 16.29M | 13.62M | 38.49M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 144K | 104.16M | 28.61M | 41.34M | 156.97M | 329.03M |
| Total Liabilities | 36.49M | 36.02M | 164.36M | 87.37M | 114.68M | 190.54M | 96.26M |
| Total Debt | 28.72M | 28.86M | 51.18M | 50.07M | 57.45M | 16.54M | 29.82M |
| Net Debt | -65M | -11.07M | -166.32M | -99.71M | -23M | -28.4M | 10.34M |
| Debt / Equity | 0.22x | 0.41x | 0.42x | 0.43x | 4.24x | - | -6.28x |
| Debt / EBITDA | - | - | - | - | - | - | -0.30x |
| Net Debt / EBITDA | - | - | - | - | - | - | -0.11x |
| Interest Coverage | -37.29x | -29.34x | -18.68x | -13.64x | -15.16x | -12.33x | -2.47x |
| Total Equity | 132.2M▲ 0% | 70.67M▼ 46.5% | 122.17M▲ 72.9% | 116.93M▼ 4.3% | 13.55M▼ 88.4% | -52.67M▼ 488.8% | -4.75M▲ 0% |
| Equity Growth % | - | -46.54% | 72.87% | -4.29% | -88.42% | -488.82% | -244.13% |
| Book Value per Share | 6.57 | 5.68 | 3.06 | 1.13 | 0.13 | -0.44 | -0.03 |
| Total Shareholders' Equity | 132.2M | 70.67M | 122.17M | 116.93M | 13.55M | -52.67M | -4.75M |
| Common Stock | 21K | 1K | 10K | 10K | 10K | 13K | 3.25M |
| Retained Earnings | -321.57M | -388.1M | -414.57M | -426.54M | -537.31M | -686.01M | -702.04M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
HUMA Cash Flow Statement
Humacyte, Inc. (HUMA) cash flow — operating, investing & free cash flow history
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -71.79M | -55.57M | -81.19M | -71.13M | -73.31M | -98.12M | -98.12M |
| Operating CF Margin % | -1160.29% | -3726.89% | -6428.35% | -4544.98% | - | - | - |
| Operating CF Growth % | - | 22.59% | -46.11% | 12.39% | -3.06% | -33.85% | -72.48% |
| Net Income | -85.42M | -66.52M | -26.48M | -11.96M | -110.78M | -148.7M | -36.97M |
| Depreciation & Amortization | 6.75M | 8.43M | 8.24M | 8.21M | 7.72M | 7.19M | 5.24M |
| Stock-Based Compensation | 4.46M | 0 | 10.15M | 6.18M | 0 | 6.14M | 6.64M |
| Deferred Taxes | -4.27M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 6.25M | 4.89M | -72.54M | -74.59M | 23.18M | 36.94M | -62.51M |
| Working Capital Changes | 453K | -2.37M | -557K | 1.03M | 6.57M | 311K | -17.89M |
| Change in Receivables | -185K | 488K | -63K | 145K | 31K | 0 | -898K |
| Change in Inventory | -2.43M | 0 | 0 | 0 | 0 | 0 | -18.27M |
| Change in Payables | 2.43M | -889K | -197K | -509K | 4.81M | -1.96M | 2.7M |
| Cash from Investing | -8.13M | -268K | -8.22M | 4.84M | -173K | -1.57M | -908K |
| Capital Expenditures | -8.13M | -318K | -220K | -1.05M | -2.28M | -1.57M | -908K |
| CapEx % of Revenue | 131.32% | 21.33% | 17.42% | 66.96% | - | - | - |
| Acquisitions | 0 | 50K | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | -74K | 2.05M | 266.98M | -1.45M | 4.51M | 114.18M | 55.32M |
| Debt Issued (Net) | -1.29M | 1.75M | 27.93M | -1.98M | 5.7M | -2.58M | -491K |
| Equity Issued (Net) | 0 | 301K | 0 | 0 | 566K | 1000K | 4M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 1.22M | 0 | 239.05M | 535K | -1.76M | 27.71M | -5.74M |
| Net Change in Cash | -79.99M▲ 0% | 39.93M▲ 149.9% | 177.57M▲ 344.7% | -67.73M▼ 138.1% | -69.18M▼ 2.1% | 14.49M▲ 120.9% | -51.23M▲ 0% |
| Free Cash Flow | -79.91M▲ 0% | -55.89M▲ 30.1% | -81.41M▼ 45.7% | -72.18M▲ 11.3% | -75.58M▼ 4.7% | -99.69M▼ 31.9% | -106.4M▲ 0% |
| FCF Margin % | -1291.61% | -3748.22% | -6445.76% | -4611.95% | - | - | -1209.26% |
| FCF Growth % | - | 30.07% | -45.67% | 11.34% | -4.72% | -31.9% | -15.33% |
| FCF per Share | -3.97 | -4.49 | -2.04 | -0.70 | -0.73 | -0.84 | -0.84 |
| FCF Conversion (FCF/Net Income) | 0.84x | 0.84x | 3.07x | 5.94x | 0.66x | 0.66x | 2.88x |
| Interest Paid | 0 | 0 | 1.12M | 2.67M | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
HUMA Key Ratios
Humacyte, Inc. (HUMA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -65.58% | -27.46% | -10.01% | -169.81% | - | 853.54% |
| Return on Invested Capital (ROIC) | -76.41% | -788.22% | - | -1930.66% | - | 867.33% |
| Gross Margin | -3526.96% | -4756.77% | -427.48% | - | - | 9.92% |
| Net Margin | -4461.7% | -2096.36% | -764.54% | - | - | -420.15% |
| Debt / Equity | 0.41x | 0.42x | 0.43x | 4.24x | - | -6.28x |
| Interest Coverage | -29.34x | -18.68x | -13.64x | -15.16x | -12.33x | -2.47x |
| FCF Conversion | 0.84x | 3.07x | 5.94x | 0.66x | 0.66x | 2.88x |
| Revenue Growth | -75.9% | -15.29% | 23.91% | -100% | - | - |
HUMA Frequently Asked Questions
Humacyte, Inc. (HUMA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Humacyte, Inc. (HUMA) reported $8.8M in revenue for fiscal year 2024. This represents a 42% increase from $6.2M in 2019.
Humacyte, Inc. (HUMA) grew revenue by 0.0% over the past year. Growth has been modest.
Humacyte, Inc. (HUMA) reported a net loss of $37.0M for fiscal year 2024.
Dividend & Returns
Humacyte, Inc. (HUMA) had negative free cash flow of $106.4M in fiscal year 2024, likely due to heavy capital investments.
Explore More HUMA
Humacyte, Inc. (HUMA) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates